Lifeward Ltd. ((LFWD)) has held its Q1 earnings call. Read on for the main highlights of the call.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Lifeward’s latest earnings call painted a cautiously optimistic picture as management balanced strategic wins against visible operational setbacks. Investors heard confidence around acquisitions, liquidity and cost controls, but near-term revenue pressure, margin compression and manufacturing disruptions kept the tone measured rather than outright bullish.
Strategic Acquisition of Oratech
Lifeward finalized an all‑equity purchase of Oratech, adding a protein oral delivery platform, including an oral insulin candidate advancing to Phase II. Management stressed that the deal was capital‑efficient, brings strategic upside and adds little near‑term cost, with no material increase in operating expenses expected.
Strengthened Balance Sheet via Financing
The company shored up liquidity with a $10 million convertible note and about $6.5 million of cash from Oratech, lifting unrestricted cash to $11.4 million from $2.2 million at year‑end 2025. This roughly $9.2 million boost provides runway to navigate the AlterG disruption while continuing to invest selectively in growth.
ReWalk Sales Growth
Despite softer overall sales, ReWalk personal exoskeleton revenue rose 11% year over year to $1.6 million from $1.3 million. Growth was fueled by international demand, broader reimbursement and expanding distribution, with Germany delivering a roughly 25% quarter‑over‑quarter increase.
Expanded Reimbursement and Distribution
The neurorehabilitation portfolio gained momentum as Lifeward secured Medicare Advantage coverage from major plans including Aetna, Humana and UnitedHealthcare. Coupled with broader domestic and international distribution, these wins support a long‑term volume and adoption ramp for ReWalk and related products.
Operating Expense Improvements (Non‑GAAP)
Adjusted operating expenses fell 12% year over year to $5.9 million from $6.8 million, showing tangible cost discipline. Savings came from more productive sales and marketing spending, lower reimbursement‑related outlays and reduced R&D after completing major programs.
Stable Adjusted Loss and Lower Cash Burn
Non‑GAAP adjusted operating loss held steady at $4.6 million despite the revenue drop, underscoring efficiency gains. Cash used in operations declined 33% to $3.7 million versus Q1 2025, helped by tighter working capital management and leaner operations.
New Upper Body Exoskeleton Opportunity
Lifeward broadened its portfolio by acquiring an upper body exoskeleton targeting roughly 4.6 million stroke survivors. Development toward commercialization is underway, and management positioned the device as a natural complement to the existing ReWalk lower‑limb platform.
Quarterly Revenue Decline
Total Q1 2026 revenue fell 22% to $3.9 million from $5.0 million a year earlier, a sharp step‑down tied mainly to AlterG. Temporary supply chain and working capital constraints curbed AlterG shipments and highlighted the operational fragility during the manufacturing transition.
Gross Margin Compression
Gross margin slid to 34.2% from 42.2%, an 800‑basis‑point hit that weighed on profitability. Management estimated that 75%–85% of the damage came from tariffs and adverse foreign exchange, with the balance tied to lower production volumes and weaker manufacturing absorption.
Higher GAAP Loss from One‑Time Charge
GAAP operating loss widened to $10.3 million, largely due to a one‑off noncash R&D and intangible asset charge of about $4.9 million tied to Oratech. Excluding this accounting impact, underlying loss metrics were more stable, but the headline figure underscored the near‑term earnings drag of the deal.
Manufacturing Transition and Supply Disruption
The closure of Lifeward’s Fremont facility and a move to contract manufacturing in Massachusetts created meaningful friction in the quarter. Timing issues, sourcing constraints and facility moves disrupted AlterG shipments, hurting revenue and lowering factory utilization.
Tariffs and FX Headwinds
Tariffs and currency moves emerged as major external headwinds, accounting for most of the gross margin erosion. While management believes some of these pressures may ease over time, the quarter showed how exposed the current model is to trade policy and FX swings.
Execution Risk on AlterG Backlog
Management highlighted a sizable backlog of secured AlterG orders that should ship over Q2 and Q3, supporting a revenue rebound. However, they warned that some issues may persist into Q2 and that a full operational normalization may not arrive until Q3, leaving execution risk elevated.
Lack of Formal 2026 Revenue Guidance
Lifeward kept its internal expectation that 2026 revenue will resemble 2025 levels but stopped short of issuing formal guidance. The decision reflects lingering uncertainty around the timing of AlterG shipment recovery and the broader manufacturing transition.
Outlook and Forward‑Looking Commentary
Looking ahead, management expects the Q1 revenue shortfall to be largely recouped in Q2–Q3 as the AlterG backlog is delivered and operations stabilize. With improved liquidity, lower adjusted opex and a clearer cost base, they outlined a path toward profitability in late 2026 or 2027, though near‑term volatility remains likely.
Lifeward’s earnings call left investors weighing solid strategic progress against real operational strain. Stronger cash reserves, exoskeleton growth and disciplined spending suggest long‑term promise, but the coming quarters will test management’s ability to fix AlterG disruptions, restore margins and turn potential into durable earnings power.